GAST and gastric neuroendocrine tumor, well differentiated, low or intermediate grade: Due to the unknown malignant potential of multiple pancreatic and gastric NETs, gastrin production short-acting SSA therapy (Octreotide 100 mcg/2 times daily) was initiated.